Benchmark downgraded AbCellera to Hold from Buy with no price target due to the negative quarterly earnings comparison reported in Q2 as well as the recent volatility for biotech stocks. For full year 2024, the firm estimates that revenues for the company will be $32.6M, as compared to $38.0M in 2023, with an increased net loss of $162.9M, or (55c) per share, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABCL:
Questions or Comments about the article? Write to editor@tipranks.com